Compare Incyte Corporation (INCY) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United States Oil ETF — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while United States Oil ETF trades at $127.77. The key difference: Incyte Corporation is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| INCY | USO | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $152.96 |
52-Week Low | $67.38 | $66.17 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
USO is trading at $125.51, up 1.25% with strong bullish momentum driven by Middle East supply disruptions. Technical indicators show overall bullish sentiment with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Recent news highlights escalating geopolitical tensions in the Strait of Hormuz, pushing oil prices higher and benefiting the fund's performance.
The outlook remains positive as supply constraints and geopolitical risks continue to support oil prices, though overbought technical conditions warrant caution. Key risks include potential conflict de-escalation and OPEC demand adjustments. Current momentum favors continued strength, but volatility remains elevated due to geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
